Skip to main content
Clinical Trials/NCT05642286
NCT05642286Not yet recruitingNot Applicable

Prospective, Multi Center, Single Group Target Value Study to Evaluate the Safety and Effectiveness of Endovascular Interventional Device Control System and Supporting Consumables for Coronary Intervention

Shanghai Operation Robot Co., Ltd.0 sites218 target enrollmentStarted: December 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
218
Primary Endpoint
Percentage of Participants With Clinical Procedural Success

Study Overview

Brief Summary

The goal of this study is to evaluate the safety and effectiveness of endovascular interventional surgery instrument control system (ALLVAS®robot)and supporting consumables for coronary artery interventional surgery.

Participants will will complete coronary intervention surgery with the assistance of robot system(ALLVAS®robot), and evaluate the effect of the use effect of robots and clinical treatment after surgery

Detailed Description

Interventional therapy plays an important role in the treatment of coronary heart disease. At present, the main treatment methods still rely on human hands, and there are some defects, including but not limited to hand shaking and visual error. The use of robots may partly circumvent the above shortcomings.

This study is to evaluate the safety and effectiveness of ALLVAS®robot for coronary artery interventional surgery.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients who voluntarily participate in and sign the informed consent form, and can cooperate to complete the whole trial process;
  • aged over 18 and under 75;
  • After coronary CT angiography (CTA) or coronary angiography (DSA), the investigator judged that the patients who needed interventional blood supply reconstruction (target vessel diameter ≥ 2.5mm and lesion stenosis ≥ 70%).

Exclusion Criteria

  • Acute myocardial infarction occurred within 7 days;
  • The target vessel has received coronary intervention within 30 days;
  • Restenosis in stent of target vessel;
  • Patients with bifurcation lesions whose target vessel branches need to be protected but cannot protect the collateral branches;
  • Hemodynamic instability (including low blood pressure or use of vasopressors to maintain blood pressure;)
  • Three vessel lesions;
  • The target vessel was diagnosed as coronary chronic occlusive disease (CTO) or left main artery stenosis or severe calcification requiring pretreatment;
  • Perforation, dissection or aneurysm of the proximal vessel of the target vessel;
  • Echocardiography showed that left ventricular ejection fraction (LVEF) was less than 50%;
  • Stroke or transient ischemic attack (TIA) occurred within 30 days;
  • Peptic ulcer or gastrointestinal bleeding within 90 days;
  • Estimated glomerular filtration rate eGFR (ckd epi)<30 ml/min/1.73 m2;
  • Platelet count<50 × 109/L or > 700 × 109/L; White blood cell count < 3 × 109/L;
  • Women who are in pregnancy or lactation or have a pregnancy preparation plan during the trial period;
  • People with allergy history or contraindication to antiplatelet drugs, anticoagulants, anesthetics, contrast agents, stent materials and their coating drugs;
  • Severe infections difficult to control;
  • Those who have mental diseases or mental disorders and cannot be described normally;
  • Emergency operation is required for any reason;
  • Those who have participated in clinical trials of other drugs or medical devices within 3 months before screening;
  • The investigator believes that there are other circumstances that are not suitable for this clinical trial.

Outcomes

Primary Outcomes

Percentage of Participants With Clinical Procedural Success

Time Frame: 3 days or hospital discharge, whichever occurs first

Defined as after the operator completed intracoronary coronary artery therapy with robot assistance, the ratio of clinically successful subjects among all enrolled subjects was reached.

Percentage of Patients With Device Technical Success

Time Frame: 1 day

Defined as after the operator completed intracoronary therapy of coronary artery with robot assistance, the ratio of successful subjects with instrument technology among all enrolled subjects was reached.

Secondary Outcomes

  • The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table(1 day)
  • Evaluation of operational performance of experimental medical devices(1 day)

Investigators

Sponsor
Shanghai Operation Robot Co., Ltd.
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials